Strategies for developing vaccines against H5N1 influenza A viruses

Trends in Molecular Medicine

Volumn 12, Issue 11, 2006, Pages 506-514

  Horimoto, Taisuke ^a   Kawaoka, Yoshihiro ^a  

^a International Research Center for Infectious Diseases   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; ADAMANTANE DERIVATIVE; ALUMINUM HYDROXIDE; ANTIVIRUS AGENT; DNA VACCINE; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OSELTAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ADENOVIRUS VECTOR; ANTIBODY RESPONSE; CELL CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; CROSS REACTION; DISEASE TRANSMISSION; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GENE SEQUENCE; GENETIC TRANSFECTION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VIRUS A; NONHUMAN; PATHOGENICITY; PHYLOGENETIC TREE; PLASMID; PROTEIN EXPRESSION; REVIEW; SEROTYPE; VACCINATION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; CERCOPITHECUS AETHIOPS; CHEMISTRY, PHARMACEUTICAL; CHICKENS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, GENETIC; MODELS, IMMUNOLOGICAL; ORTHOMYXOVIRIDAE INFECTIONS; VERO CELLS; VIRULENCE FACTORS; VIRUS REPLICATION;

AVES; INFLUENZA A VIRUS;

EID: 33750986171     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.09.003     Document Type: Review

References (76)

1. Lamb R.A., and Krug R.M. Orthomyxoviridae: the viruses and their replication. In: Knipe D.M., et al. (Ed). Fields Virology. 4th edn (2001), Lippincott-Raven 1487-1531
2. Wright P.F., and Webster R.G. Orthomyxoviruses. In: Knipe D.M., et al. (Ed). Fields Virology. 4th edn (2001), Lippincott-Raven 1533-1579
3. Fouchier R.A., et al. Characterization of a novel influenza a virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79 (2005) 2814-2822
4. Horimoto T., and Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin. Microbiol. Rev. 14 (2001) 129-149
5. Johnson N.P., and Mueller J. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. Bull. Hist. Med. 76 (2002) 105-115
6. Reid A.H., et al. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat. Rev. Microbiol. 2 (2004) 909-914
7. Gamblin S.J., et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303 (2004) 1838-1842
8. Stevens J., et al. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303 (2004) 1866-1870
9. Kobasa D., et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431 (2004) 703-707
10. Tumpey T.M., et al. Characterization of the reconstituted 1918 Spanish influenza pandemic virus. Science 310 (2005) 77-80
11. Horimoto T., and Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3 (2005) 591-600
12. Matrosovich M., et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J. Virol. 74 (2000) 8502-8512
13. Beare A.S., and Webster R.G. Replication of avian influenza viruses in humans. Arch. Virol. 119 (1991) 37-42
14. Subbarao K., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 (1998) 393-396
15. Claas E.C.J., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 (1998) 472-477
16. Buxton Bridges C., et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J. Infect. Dis. 181 (2000) 344-348
17. Xu X., et al. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261 (1999) 15-19
18. Cauthen A.N., et al. Continued circulation in China of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J. Virol. 74 (2000) 6592-6599
19. Guan Y., et al. H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8156-8161
20. Sturm-Ramirez K.M., et al. Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J. Virol. 78 (2004) 4892-4901
21. Peiris J.S., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004) 617-619
22. Li K.S., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 (2004) 209-213
23. World Health Organization Global Influenza Program Surveillance Network (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515-1521
24. Chen H., et al. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature 436 (2005) 191-192
25. Liu J., et al. Highly pathogenic H5N1 influenza virus infection in migratory birds. Science 309 (2005) 1206
26. Enserink M., and Kaiser J. Avian flu finds new mammal hosts. Science 305 (2004) 1385
27. Kuiken T., et al. Avian H5N1 influenza in cats. Science 306 (2004) 241
28. Tran T.H., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350 (2004) 1179-1188
29. Ungchusak K., et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352 (2005) 333-340
30. Shinya K., et al. Avian flu: influenza virus receptors in the human airway. Nature 440 (2006) 435-436
31. van Riel D., et al. H5N1 virus attachment to lower respiratory tract. Science 312 (2006) 399
32. Matrosovich M., et al. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4620-4624
33. Hatta M., et al. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293 (2001) 1840-1842
34. Seo S., et al. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat. Med. 8 (2002) 950-954
35. Geiss G.K., et al. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10736-10741
36. Crumpacker C. Antiviral therapy. In: Knipe D.M., et al. (Ed). Fields Virology. 4th edn (2001), Lippincott-Raven 393-433
37. Gubareva L.V., et al. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
38. Matrosovich M.N., et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78 (2004) 12665-12667
39. Yen H.L., et al. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192 (2005) 665-672
40. Gubareva L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103 (2004) 199-203
41. Kiso M., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
42. Le Q.M., et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
43. Gupta R.K., et al. Oseltamivir resistance in influenza A (H5N1) infection. N. Engl. J. Med. 354 (2006) 1423-1424
44. Nicholson K.G., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
45. Stephenson I., et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect. Dis. 4 (2004) 499-509
46. Stephenson I., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191 (2005) 1210-1215
47. Neumann G., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9345-9350
48. Hoffmann E., et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6108-6113
49. Fodor E., et al. Rescue of influenza A virus from recombinant DNA. J. Virol. 73 (1999) 9679-9682
50. Horimoto T., and Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J. Virol. 68 (1994) 3120-3128
51. Luytjes W., et al. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59 (1989) 1107-1113
52. Stieneke-Gröber A., et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 11 (1992) 2407-2414
53. Takada A., et al. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol. 73 (1999) 8303-8307
54. Webby R.J., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 (2004) 1099-1103
55. Wood J.M., and Robertson J.S. From lethal virus to life-saving vaccine: the development of inactivated influenza vaccines for pandemic influenza. Nat. Rev. Microbiol. 2 (2004) 842-847
56. Subbarao K., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 (2003) 192-200
57. Horimoto T., et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24 (2006) 3669-3676
58. Nicolson C., et al. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
59. Treanor J.J., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
60. Treanor J.J., et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354 (2006) 1343-1351
61. Bresson J.L., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
62. Condon C. A vaccine in 50 days?. Lancet 366 (2005) 1686
63. Lipatov A.S., et al. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J. Infect. Dis. 191 (2005) 1216-1220
64. Govorkova E.A., et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194 (2006) 159-167
65. Medema J.K., et al. Safety assessment of Madin Darby canine kidney cells as vaccine substrate. Dev. Biol. (Basel) 123 (2006) 243-250
66. Li S., et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis. 179 (1999) 1132-1138
67. Beyer W.E.P., et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20 (2002) 1340-1353
68. Hoelscher M.A., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 (2006) 475-481
69. Gao W., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80 (2006) 1959-1964
70. Neumann G., et al. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16825-16829
71. Forde G.M. Rapid-response vaccines - does DNA offer a solution?. Nat. Biotechnol. 23 (2005) 1059-1062
72. De Filette M., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 (2005) 149-161
73. Hehme N., et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med. Microbiol. Immunol. (Berl.) 191 (2002) 203-208
74. Stephenson I., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 (2003) 1959-1966
75. de Wit E., et al. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J. Virol. 79 (2005) 12401-12407
76. Longini I.M., et al. Containing pandemic influenza at the source. Science 309 (2005) 1083-1087